ABC | Volume 112, Nº6, June 2019

Viewpoint Beck-da-Silva & Rodhe The diuretic effect of Sacubitril/Valsartan Arq Bras Cardiol. 2019; 112(6):791-792 1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. 2. Cohn JN, Tognoni G, the ValsartanHeart Failure Trial I. A randomized trial of the angiotensin-receptor blocker Valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667-75. 3. AyalasomayajulaS,SchuehlyU,PalP,ChenF,ZhouW,SunkaraG,etal.Effect of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide. Br J Clin Pharmacol. 2018;84(5):926-36. 4. YilmazMB, Gayat E, SalemR, Lassus J, NikolaouM, Laribi M, et al. Impact of diureticdosingonmortality inacuteheart failureusingapropensity-matched analysis. Eur J Heart Fail. 2011;13(11):1244-52. 5. Felker GM, Lee KL, Bull DA, Redflield MM, Stevenson LW, Goldsmith SR, et al. et al. Diuretic Strategies in Patients with Acute Decompensated Heart Failure. N Engl L Med. 2011;364(9):797-805. 6. da Rosa PR, Rohde LE, Doebber M,Ribeiro ALP, Prado DP, Bertoldi FG, et al. Rationalanddesignofarandomized,double-blind,multicentertrialtoevaluate thesafetyandtolerabilityoffurosemidewithdrawalinstablechronicoutpatients with heart failure: The ReBIC-1 trial. AmHeart J. 2017Dec ;194:125-31. References This is an open-access article distributed under the terms of the Creative Commons Attribution License 792